SynthesisRheumatology (Oxford, England)2025
Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis.
Synthesis in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence and Clinical Associations of Systemic Sclerosis-Related Autoantibodies: A Nationwide Reuma.pt Cohort Study.Antibodies (Basel, Switzerland) · 2026Article
- Association between pregnancy outcomes prior to diagnosis and clinical characteristics following diagnosis in patients with systemic sclerosis.Clinical rheumatology · 2026Article
- Skin Transcriptomics Reveal Shared Molecular Mechanisms for Skin and Lung Involvement in Systemic Sclerosis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Triple-Positive Serology in Rapidly Progressive Glomerulonephritis: A Diagnostic Dilemma.Kidney medicine · 2026Article
- Chromosomal Instability and Telomere Attrition in Systemic Sclerosis: A Historical Perspective.Genes · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesAnti-RNA polymerase III antibodies (ARA) are frequent in systemic sclerosis (SSc). However, the reported prevalence is variable among studies and some clinical associations are debated. We aimed (i) to update the recent data on overall ARA prevalence in SSc and heterogeneity between centres; and (ii) to describe their clinical associations.
methodsA systematic review of the literature available up to June 2024 was carried out in Pubmed and Embase. Meta-analyses were performed to assess the prevalence and clinical associations of ARA in SSc, combined with meta-regressions in case of heterogeneity to identify potential cofactors.
resultsNinety-three studies corresponding to a total of 23 038 SSc patients were included in the meta-analysis. In this population, the overall seroprevalence of ARA was 9% (95% CI: 8-10) with a high degree of heterogeneity (I2 = 88%, P < 0.001). ARA positivity was significantly associated with diffuse cutaneous subset (OR: 2.20 [1.91-2.53]), joint manifestations (OR: 1.29 [1.01-1.66]), gastric antral vascular ectasia (GAVE) (OR: 2.70 [1.52-4.81]), heart involvement (OR: 1.93 [1.18-3.18]), scleroderma renal crisis (OR: 7.82 [5.79-10.57]), interstitial lung disease (ILD) (OR: 1.10 [1.00-1.20]) and cancer (OR: 1.86 [1.33-2.59]).
conclusionThis study provides an overall seroprevalence of ARA of 9% [8-10] and confirms that SSc patients with ARA are at higher risk of severe skin extension and renal crisis. It also highlights a positive association with cancer, GAVE, heart, joint involvement and ILD. ARA positive SSc patients could therefore benefit from an appropriate screening of these potentially severe complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.